Publication

Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics

Purba, A. K. R., Setiawan, D., Bathoorn, E., Postma, M. J., Dik, J-W. H. & Friedrich, A. W., 18-Jul-2018, In : Frontiers in Pharmacology. 9, 776.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Purba, A. K. R., Setiawan, D., Bathoorn, E., Postma, M. J., Dik, J-W. H., & Friedrich, A. W. (2018). Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics. Frontiers in Pharmacology, 9, [776]. https://doi.org/10.3389/fphar.2018.00776

Author

Purba, Abdul K R ; Setiawan, Didik ; Bathoorn, Erik ; Postma, Maarten J ; Dik, Jan-Willem H ; Friedrich, Alex W. / Prevention of Surgical Site Infections : A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics. In: Frontiers in Pharmacology. 2018 ; Vol. 9.

Harvard

Purba, AKR, Setiawan, D, Bathoorn, E, Postma, MJ, Dik, J-WH & Friedrich, AW 2018, 'Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics', Frontiers in Pharmacology, vol. 9, 776. https://doi.org/10.3389/fphar.2018.00776

Standard

Prevention of Surgical Site Infections : A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics. / Purba, Abdul K R; Setiawan, Didik; Bathoorn, Erik; Postma, Maarten J; Dik, Jan-Willem H; Friedrich, Alex W.

In: Frontiers in Pharmacology, Vol. 9, 776, 18.07.2018.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Purba AKR, Setiawan D, Bathoorn E, Postma MJ, Dik J-WH, Friedrich AW. Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics. Frontiers in Pharmacology. 2018 Jul 18;9. 776. https://doi.org/10.3389/fphar.2018.00776


BibTeX

@article{f42bcdf08f5247cc96b2b117b77ff62a,
title = "Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics",
abstract = "Introduction: The preoperative phase is an important period in which to prevent surgical site infections (SSIs). Prophylactic antibiotic use helps to reduce SSI rates, leading to reductions in hospitalization time and cost. In clinical practice, besides effectiveness and safety, the selection of prophylactic antibiotic agents should also consider the evidence with regard to costs and microbiological results. This review assessed the current research related to the use of antibiotics for SSI prophylaxis from an economic perspective and the underlying epidemiology of microbiological findings. Methods: A literature search was carried out through PubMed and Embase databases from 1 January 2006 to 31 August 2017. The relevant studies which reported the use of prophylactic antibiotics, SSI rates, and costs were included for analysis. The causing pathogens for SSIs were categorized by sites of the surgery. The quality of reporting on each included study was assessed with the {"}Consensus on Health Economic Criteria{"} (CHEC). Results: We identified 20 eligible full-text studies that met our inclusion criteria, which were subsequently assessed, studies had in a reporting quality scored on the CHEC list averaging 13.03 (8-18.5). Of the included studies, 14 were trial-based studies, and the others were model-based studies. The SSI rates ranged from 0 to 71.1% with costs amounting to US$480-22,130. Twenty-four bacteria were identified as causative agents of SSIs. Gram negatives were the dominant causes of SSIs especially in general surgery, neurosurgery, cardiothoracic surgery, and obstetric cesarean sections. Conclusions: Varying results were reported in the studies reviewed. Yet, information from both trial-based and model-based costing studies could be considered in the clinical implementation of proper and efficient use of prophylactic antibiotics to prevent SSIs and antimicrobial resistance.",
author = "Purba, {Abdul K R} and Didik Setiawan and Erik Bathoorn and Postma, {Maarten J} and Dik, {Jan-Willem H} and Friedrich, {Alex W}",
year = "2018",
month = jul,
day = "18",
doi = "10.3389/fphar.2018.00776",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media SA",

}

RIS

TY - JOUR

T1 - Prevention of Surgical Site Infections

T2 - A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics

AU - Purba, Abdul K R

AU - Setiawan, Didik

AU - Bathoorn, Erik

AU - Postma, Maarten J

AU - Dik, Jan-Willem H

AU - Friedrich, Alex W

PY - 2018/7/18

Y1 - 2018/7/18

N2 - Introduction: The preoperative phase is an important period in which to prevent surgical site infections (SSIs). Prophylactic antibiotic use helps to reduce SSI rates, leading to reductions in hospitalization time and cost. In clinical practice, besides effectiveness and safety, the selection of prophylactic antibiotic agents should also consider the evidence with regard to costs and microbiological results. This review assessed the current research related to the use of antibiotics for SSI prophylaxis from an economic perspective and the underlying epidemiology of microbiological findings. Methods: A literature search was carried out through PubMed and Embase databases from 1 January 2006 to 31 August 2017. The relevant studies which reported the use of prophylactic antibiotics, SSI rates, and costs were included for analysis. The causing pathogens for SSIs were categorized by sites of the surgery. The quality of reporting on each included study was assessed with the "Consensus on Health Economic Criteria" (CHEC). Results: We identified 20 eligible full-text studies that met our inclusion criteria, which were subsequently assessed, studies had in a reporting quality scored on the CHEC list averaging 13.03 (8-18.5). Of the included studies, 14 were trial-based studies, and the others were model-based studies. The SSI rates ranged from 0 to 71.1% with costs amounting to US$480-22,130. Twenty-four bacteria were identified as causative agents of SSIs. Gram negatives were the dominant causes of SSIs especially in general surgery, neurosurgery, cardiothoracic surgery, and obstetric cesarean sections. Conclusions: Varying results were reported in the studies reviewed. Yet, information from both trial-based and model-based costing studies could be considered in the clinical implementation of proper and efficient use of prophylactic antibiotics to prevent SSIs and antimicrobial resistance.

AB - Introduction: The preoperative phase is an important period in which to prevent surgical site infections (SSIs). Prophylactic antibiotic use helps to reduce SSI rates, leading to reductions in hospitalization time and cost. In clinical practice, besides effectiveness and safety, the selection of prophylactic antibiotic agents should also consider the evidence with regard to costs and microbiological results. This review assessed the current research related to the use of antibiotics for SSI prophylaxis from an economic perspective and the underlying epidemiology of microbiological findings. Methods: A literature search was carried out through PubMed and Embase databases from 1 January 2006 to 31 August 2017. The relevant studies which reported the use of prophylactic antibiotics, SSI rates, and costs were included for analysis. The causing pathogens for SSIs were categorized by sites of the surgery. The quality of reporting on each included study was assessed with the "Consensus on Health Economic Criteria" (CHEC). Results: We identified 20 eligible full-text studies that met our inclusion criteria, which were subsequently assessed, studies had in a reporting quality scored on the CHEC list averaging 13.03 (8-18.5). Of the included studies, 14 were trial-based studies, and the others were model-based studies. The SSI rates ranged from 0 to 71.1% with costs amounting to US$480-22,130. Twenty-four bacteria were identified as causative agents of SSIs. Gram negatives were the dominant causes of SSIs especially in general surgery, neurosurgery, cardiothoracic surgery, and obstetric cesarean sections. Conclusions: Varying results were reported in the studies reviewed. Yet, information from both trial-based and model-based costing studies could be considered in the clinical implementation of proper and efficient use of prophylactic antibiotics to prevent SSIs and antimicrobial resistance.

U2 - 10.3389/fphar.2018.00776

DO - 10.3389/fphar.2018.00776

M3 - Article

C2 - 30072898

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 776

ER -

ID: 63934936